SRR6013491
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- MYC_TARGETS_V1+0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- ADIPOGENESIS+0.440
- OXIDATIVE_PHOSPHORYLATION+0.440
- GLYCOLYSIS+0.410
- MTORC1_SIGNALING+0.410
- TGF_BETA_SIGNALING+0.360
- CHOLESTEROL_HOMEOSTASIS+0.350
- FATTY_ACID_METABOLISM+0.350
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.270
- KRAS_SIGNALING_DN-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- ANGIOGENESIS-0.200
- SPERMATOGENESIS-0.190
- MYOGENESIS-0.180
- PANCREAS_BETA_CELLS-0.150
- HEDGEHOG_SIGNALING-0.110
- APICAL_SURFACE-0.090
- PI3K_AKT_MTOR_SIGNALING+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.855 |
| 2 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.843 |
| 3 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.842 |
| 4 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.839 |
| 5 | SRR934931 | — | — | 0.838 |
| 6 | C9523C23-CF9B-4C33-A256-4106AD46729D | — | — | 0.837 |
| 7 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.828 |
| 8 | MNG590 | — | — | 0.827 |
| 9 | SRR6013490 | — | cohortA4 | 0.824 |
| 10 | SRR1797239 | — | cohortSC | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |